ISOTECHNIKA PHARMA INC : 26 Nov 2012 - Isotechnika Cleared by FDA to ... 4-traders The primary endpoint of the trial will be defined as non-inferiority in biopsy proven acute rejection, or BPAR, episodes with patients receiving voclosporin for six months as compared to tacrolimus. A key secondary endpoint will be the incidence of ... |
